Asset
BEMNIFOSBUVIR SULFATE
Atea Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04877769 | phase1 | completed | 2021-04-25 | 2021-08-31 | Atea Pharmaceuticals, Inc. | Bronchopulmonary PK of AT-527 (R07496998) |
| NCT05137626 | phase1 | completed | 2021-11-03 | 2021-12-12 | Atea Pharmaceuticals, Inc. | Drug-drug Interaction Study of Digoxin and AT-527 (R07496998) |
| NCT04865445 | phase1 | completed | 2021-04-22 | 2021-05-15 | Atea Pharmaceuticals, Inc. | Drug-drug Interaction Study of Midazolam and AT-527 (R07496998) |
| NCT05154123 | phase1 | completed | 2021-11-16 | 2021-12-23 | Atea Pharmaceuticals, Inc. | Drug-drug Interaction Study of Rosuvastatin and AT-527 (R07496998) |
| NCT04849299 | phase1 | completed | 2021-04-18 | 2021-05-10 | Atea Pharmaceuticals, Inc. | Effect of Cyclosporine on the Pharmacokinetics (PK) of AT-527 (R07496998) |
FDA applications (0)
This company has no applications containing this asset.